Amneal (AMRX) Q2 FY26 earnings call

Amneal Pharmaceuticals delivered strong Q2 FY26 results, driven by momentum in Affordable Medicines and Specialty segments, leading to a raised full-year outlook. The company is undergoing a transformative period, focusing on biosimilars through the Kashiv acquisition, expanding its complex generics portfolio, and advancing its Specialty pipeline, including a GLP-1 partnership, to become a leader in affordable and essential medicines.